Global Psoriasis Therapeutics Market Size By Type (TNF Inhibitors, PDE4 Inhibitors), By Application (Oral, Parenteral), By Region, And Segment Forecasts, 2023 to 2032

The Global Psoriasis Therapeutics Market was valued at USD 27.5 billion in 2023 and is projected to surpass USD 45.8 billion by 2031, growing at a CAGR of 6.5% during the forecast period of 2023-2031. The increasing prevalence of psoriasis, advancements in biologic and systemic treatments, and growing awareness about disease management are key factors driving the market growth.

Psoriasis, a chronic autoimmune skin disease, affects millions globally, leading to rising demand for effective treatment options. With ongoing research in novel therapeutics and personalized medicine approaches, the psoriasis therapeutics market is expected to witness steady expansion.

Drivers

1. Rising Prevalence of Psoriasis

The growing number of psoriasis patients globally is a major driver for the market. Factors such as genetics, environmental triggers, and increasing cases of lifestyle-related disorders like obesity and stress contribute to the rising incidence of psoriasis.

2. Advancements in Biologic Therapies

Innovations in biologics and targeted therapies have transformed psoriasis treatment, offering better efficacy and fewer side effects than traditional systemic treatments. IL-17 and IL-23 inhibitors are gaining traction, boosting market demand.

3. Increased Awareness and Diagnosis

Government initiatives and patient advocacy groups are actively promoting awareness, leading to early diagnosis and improved treatment adherence. This, in turn, enhances market growth.

Restraints

1. High Cost of Biologics and Targeted Therapies

The cost of advanced biologics remains a significant barrier, limiting access to patients in low- and middle-income countries. While biosimilars are expected to address affordability, the pricing challenge persists.

2. Side Effects and Long-Term Risks

Although biologics offer high efficacy, potential side effects such as immunosuppression, increased infection risk, and organ complications hinder widespread adoption.

Opportunity

1. Expansion in Emerging Markets

Increasing healthcare expenditure and improved access to dermatological treatments in Asia-Pacific and Latin America present lucrative growth opportunities for market players.

2. Personalized Medicine and Precision Therapeutics

The integration of genetic and molecular profiling is paving the way for personalized psoriasis treatments, enhancing patient outcomes and boosting demand for novel therapeutics.

Market by Drug Type Insights

Biologic Drugs dominated the market in 2023, accounting for the largest share due to their superior efficacy in moderate to severe psoriasis cases. Key biologics include TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors.

Topical Therapies remain widely used for mild psoriasis cases, with corticosteroids and vitamin D analogs being the most prescribed.

Systemic Drugs (oral small molecules like PDE4 inhibitors and JAK inhibitors) are witnessing rising adoption due to their convenience and effectiveness in treating moderate psoriasis cases.

Market by End-use Insights

Hospitals & Specialty Clinics accounted for the largest market share in 2023, driven by increased access to advanced treatment options and specialist consultations.

Retail & Online Pharmacies are witnessing growth due to the rising availability of prescription treatments through digital platforms.

Market by Regional Insights

North America led the global psoriasis therapeutics market in 2023, holding the largest market share due to high disease prevalence, well-established healthcare infrastructure, and the presence of major pharmaceutical companies.

Europe is the second-largest market, driven by increasing biologic drug adoption and favorable reimbursement policies.

Asia-Pacific is expected to witness the fastest growth during the forecast period, fueled by growing awareness, increasing healthcare spending, and the expansion of dermatology clinics.

Competitive Scenario

Key players operating in the Global Psoriasis Therapeutics Market include:

AbbVie Inc.

Novartis International AG

Johnson & Johnson

Eli Lilly and Company

Amgen Inc.

UCB S.A.

Pfizer Inc.

Boehringer Ingelheim

Bristol-Myers Squibb Company

Sun Pharmaceutical Industries Ltd.

These companies focus on product innovations, strategic collaborations, and clinical trials to expand their market presence. For example:

In 2023, AbbVie received FDA approval for Rinvoq (upadacitinib) for moderate-to-severe psoriasis, expanding its immunology portfolio.

In 2024, Novartis launched a next-generation IL-17 inhibitor with improved safety and efficacy profiles.

In 2025, Eli Lilly announced a global expansion of its dermatology drug Taltz (ixekizumab) into emerging markets.

Scope of Work – Global Psoriasis Therapeutics Market

Key Market Developments

January 2023 – Pfizer introduced a new oral small-molecule treatment for plaque psoriasis, offering an alternative to biologic therapy.

July 2023 – Amgen announced the expansion of its dermatology research pipeline, focusing on next-generation immunomodulatory treatments.

December 2023 – UCB S.A. launched a novel IL-23 inhibitor for psoriasis treatment, entering a highly competitive segment.

FAQs

1. What is the current market size of the Global Psoriasis Therapeutics Market?

The market was valued at USD 27.5 billion in 2023 and is projected to reach USD 45.8 billion by 2031.

2. What is the major growth driver of the Global Psoriasis Therapeutics Market?

The increasing prevalence of psoriasis and advancements in biologic and systemic therapies are major drivers.

3. Which is the largest region during the forecast period in the Global Psoriasis Therapeutics Market?

North America holds the largest market share, driven by high psoriasis prevalence and strong pharmaceutical industry presence.

4. Which segment accounted for the largest market share in the Global Psoriasis Therapeutics Market?

The Biologic Drugs segment accounted for the largest market share due to its high efficacy in treating moderate-to-severe psoriasis.

5. Who are the key market players in the Global Psoriasis Therapeutics Market?

Major players include AbbVie, Novartis, Johnson & Johnson, Eli Lilly, Amgen, UCB, Pfizer, and Boehringer Ingelheim, among others.

This comprehensive report provides in-depth insights into the Global Psoriasis Therapeutics Market, covering key drivers, restraints, opportunities, competitive landscape, and future market projections. 🚀